Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
about
Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastomaThe natural history of EGFR and EGFRvIII in glioblastoma patientsCase comparison and literature review of glioblastoma: A tale of two tumorsPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.MRI findings and pathological features in early-stage glioblastoma.The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.Phenotype vs genotype in the evolution of astrocytic brain tumors.Amplification and overexpression of mdm2 gene in ependymomas.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesConnection between Cell Phone use, p53 Gene Expression in Different Zones of Glioblastoma Multiforme and Survival PrognosesGene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation modelDetailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy.p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variablesPediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.Delivery systems and molecular targets of mechanism-based therapies for GBM.Epidermal growth factor receptor is related to poor survival in glioblastomas: single-institution experience.The prognostic influence of bcl-2 in malignant gliomaMechanisms of chemoresistance to alkylating agents in malignant glioma.Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.EGF receptor variant III as a target antigen for tumor immunotherapy.Prognostic markers of astrocytoma: how to predict the unpredictable?1H NMR detects different metabolic profiles in glioblastoma stem-like cells.Ryk is essential for Wnt-5a-dependent invasiveness in human glioma.Impact of genotype and morphology on the prognosis of glioblastoma.Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis.Probabilistic radiographic atlas of glioblastoma phenotypes.Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme.Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining.Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China.Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas.Molecular markers of prognosis in astrocytic tumors.
P2860
Q24548280-18E32899-8EA8-4FB5-B5C1-DBCDED14AD44Q24814477-9E618820-D922-45D7-9815-39D6765ACFC6Q27014996-50C3EBCF-9783-401D-9839-1142E8BBED07Q30365539-2AC410AF-9D06-41F7-AF35-2A97E88D1C54Q30456087-CAC752FB-6DF9-45F5-A505-01B9610B27F8Q30943758-43F4423A-9485-4A6C-9163-EE192C78671AQ33794860-F8F4A7C4-B2BA-4D3A-A22E-F9A7B2DD465FQ33809397-688EE133-C661-42CB-8F78-4A2D0F8B64C0Q33834813-85C07A9C-1860-4022-9F1B-36DAC067D535Q33902910-C03138BD-69D2-44C5-827C-33FA1F559F03Q33925544-CC373113-15EE-4741-8D3D-71CCA59B6751Q34259181-7A533DA5-2492-4FF6-9481-D3EDBC50F4BAQ35069587-CF652905-A319-42D7-84D1-A8FAF9F085BBQ35356484-35E88E94-CD0B-491B-965E-1871428AEB62Q35454275-ABE92DE1-750D-4913-9034-51027C8EF33CQ35473890-87C8ED9D-D84A-4C57-8662-86997EF8B819Q35800058-0D47EEA3-4614-442C-8704-AEB10F56680AQ35800128-6C2339C1-77AD-418B-8EBB-5C05C064C8FEQ35842014-AC60486D-A2C5-4EFE-9B80-2B793F7C6D61Q36107160-489C86F0-C39C-4A58-863F-F7E78F3F4E6BQ36463850-BC205CD4-BD16-4DDF-BEE7-3DA21EF31CA6Q36644672-84EF8B69-EC3E-4147-A0A8-D817ACF77D63Q36726010-4FD7A2CD-B2E0-4B22-A913-189292639AA0Q37110440-6936469C-7953-4BA5-B758-BCF0CBEE1B1EQ37259602-C10D80E8-AA34-4D2D-B072-59C43D9F89D0Q38089921-7ED9F6BB-8BC9-4CFC-BE26-9CF156E14D7AQ38311800-0D0B2D42-670C-4726-8611-7A478500EFC8Q39016263-64EB4F02-104D-4C64-8B3D-A9F855932B49Q39599088-EC290681-AA53-4174-A873-3A1DB7125559Q40769882-5D1EC0D1-E78E-4962-9F2B-C889CB4FD392Q43133266-A239DFD1-5583-4C4B-B700-E4C127BD2C28Q44021954-BC2A4E41-A54C-4883-A2DA-1C3C7E6C7583Q44022504-1FC12D89-30D1-4F1B-AD4A-E269C917104DQ44495962-8EE332B6-72E4-4FDE-B69A-15EFF73CAB1BQ45372198-B7803D00-4851-44DB-8C60-A19D8EDD14E4Q46924276-7409E513-4117-452B-B557-7E6FC12AE648Q47193646-CDC387B4-2778-4320-BF54-9DF127F85473Q48376998-97A81801-7133-4665-8D7E-DC3ABA41E227Q48394951-9C0801B4-35D3-4E10-BEFD-66B22773BCDFQ48514271-DD552AC8-9E1C-45C6-8374-07EEB5C3CB91
P2860
Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@en
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@nl
type
label
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@en
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@nl
prefLabel
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@en
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@nl
P2093
P2860
P1433
P1476
Survival of patients with glio ...... 53, EGFR, MDM2 or Bcl-2 genes.
@en
P2093
D C Miller
E W Newcomb
S K Bhalla
P2860
P304
P356
10.1111/J.1750-3639.1998.TB00191.X
P577
1998-10-01T00:00:00Z